Key Highlights

  • Nurix Therapeutics (NASDAQ:NRIX) slid 41.91% to USD 15.00 after Sanofi opted to discontinue a Phase 1 STAT6 degrader effort, even though the company reports USD 1.1 billion in cash as of August 31, 2026.
  • Supernus (NASDAQ:SUPN) was quoted 34.04% lower at USD 27.65 following the Indivior combination that closed on November 2, 2026. That move may be comparing two different share bases, since holders received 1.5401 shares for each old share.
  • Cerenome (NASDAQ:CNSY) fell 31.96% to USD 0.88, and no company announcement dated November 2 to November 4, 2026 turned up. Its Market Value sits near USD 6.71 million.
  • BioVie (NASDAQ:BIVI) dropped 19.08% and UroGen Pharma (NASDAQ:URGN) fell 18.14%. BioVie had just priced a USD 4.74 million offering at USD 1.60, while UroGen trimmed its JELMYTO outlook to about USD 90 million from a previous USD 97 million to USD 101 million range.

Nurix Therapeutics (NASDAQ:NRIX): Off 41.91% as Sanofi Discontinues a Program

Nurix Therapeutics (NASDAQ:NRIX) traded at USD 15.00 during the November 4, 2026 session, down 41.91%, a decline of USD 10.82 from an implied prior close near USD 25.82 (calculated). Pre-market the slide had reached roughly 28%, and it deepened once trading was underway. The trigger was a company release dated November 3, 2026, issued after the close, which said Sanofi had decided to halt the Phase 1 trial of SAR448272, an oral STAT6 degrader, and to end the program. No reasons from Sanofi were given. Nurix no longer anticipates any milestone payments or royalties tied to this program, although it remains eligible for payments on other licensed programs. Cash, equivalents and marketable securities stood at USD 1.1 billion on August 31, 2026, and the runway into the second half of 2029 is unchanged. Published coverage said Jefferies cut its target to USD 36 from USD 45 while keeping a Buy rating. Nurix Therapeutics (NASDAQ:NRIX) depends on Roche for the Phase 3 bexobrutideg program in chronic lymphocytic leukemia, and partners can exit early-stage programs with little warning.

Supernus (NASDAQ:SUPN): Down 34.04% After the Indivior Merger

Supernus (NASDAQ:SUPN) was quoted at USD 27.65, down 34.04% in intraday data on November 4, 2026. That implies a prior close near USD 41.92 and a fall of USD 14.27 (calculated). The Indivior Merger closed on November 2, 2026, and the combined company, Supernus, Inc., started trading as SUPN on November 3. Each old Supernus Pharmaceuticals share was converted into 1.5401 Indivior shares, and Indivior holders received a USD 1.0 billion special Cash Dividend funded by a USD 650 million term Loan plus existing cash. Multiplying USD 27.65 by 1.5401 gives about USD 42.58, close to the calculated prior close, which points to a basis mismatch. This is our interpretation, not a company statement. Former Indivior holders own about 56.5% of Supernus (NASDAQ:SUPN), while former Supernus holders own about 43.5%. Third quarter Revenue was USD 226.8 million, up 18%, and the new Debt brings interest costs that the standalone figures did not include.

Cerenome (NASDAQ:CNSY): Down 31.96% With No New Announcement

Cerenome (NASDAQ:CNSY) was quoted at USD 0.8800, down 31.96% in intraday data on November 4, 2026, implying a prior close near USD 1.2934 and a decline of USD 0.4134 (calculated). No company announcement dated November 2 to November 4 was identified, so the move is treated as trading-driven. Cerenome is the name Plus Therapeutics took on in August 2026, and it calls itself an integrated CNS oncology company with the CNSide diagnostic platform and the REYOBIQ radiotherapeutic candidate. A September 30, 2026 presentation said CMS final pricing for a reimbursement code is expected in November 2026. A Facility of up to USD 20 million with 3i, LP, announced on September 10, 2026, is repaid through royalties, with later tranches linked to milestones. The presentation also refers to Going Concern risk. With a market value near USD 6.71 million, Cerenome (NASDAQ:CNSY) can swing on just a few trades, and quoted moves can reverse.

BioVie (NASDAQ:BIVI): Down 19.08% After a USD 4.74 Million Offering

BioVie (NASDAQ:BIVI) was quoted at USD 1.40 in regular trading on November 4, 2026, down 19.08%, which implies a prior close of USD 1.73 and a loss of USD 0.33 (calculated). A company release dated November 4 announced a registered direct offering plus a concurrent private placement. One healthcare-focused institutional investor agreed to buy 2,962,500 shares at USD 1.60, along with unregistered warrants for the same number of shares at USD 1.70, exercisable six months after issuance and expiring five and a half years after it. Gross proceeds are about USD 4.74 million before commissions, and closing is expected on or about November 5, 2026. Set against an intraday market value of about USD 11.94 million, the raise equals roughly 40% of that value (simple arithmetic on two published numbers). BioVie (NASDAQ:BIVI) has no approved product, so financing terms shape how each raise should be read. A limited number of trades can move the price, and nothing here suggests the decline will continue.

UroGen Pharma (NASDAQ:URGN): Down 18.14% After a JELMYTO Guidance Cut

UroGen Pharma (NASDAQ:URGN) was quoted at USD 28.16 intraday on November 4, 2026, down 18.14%, implying a prior close of USD 34.40 and a decline of USD 6.24 (calculated). The timing lines up with a company release issued at 8:00 a.m. ET. Total third quarter revenue reached USD 89.0 million, with ZUSDURI contributing USD 68.0 million, up 35% from the second quarter, and 1,538 activated sites of care. JELMYTO brought in USD 21.0 million, and 2026 JELMYTO guidance was lowered to about USD 90 million, citing a one-time CMS-related adjustment and competing trial enrollment. Published coverage described revenue as below estimates, but the consensus figure was not verified. The net loss narrowed to USD 1.5 million, yet cash and marketable securities fell to USD 90.5 million and the Balance Sheet shows a shareholders' deficit. UroGen Pharma (NASDAQ:URGN) has a June 14, 2027 PDUFA goal date for UGN-103, and its JELMYTO sales support debt service while ZUSDURI scales.

Where Things Stand

Nurix Therapeutics (NASDAQ:NRIX) was the largest healthcare decliner at 41.91%, and the five share a story tied to financing or partner developments rather than clinical failures reported by the companies. Supernus (NASDAQ:SUPN) may reflect a merger basis mismatch. Cerenome (NASDAQ:CNSY) had no identified catalyst. BioVie (NASDAQ:BIVI) sold new shares and warrants. UroGen Pharma (NASDAQ:URGN) trimmed a product forecast. Readers should check the closing of the BioVie offering, Nurix partner updates and the UroGen 10-Q, since small-cap healthcare moves can reverse as data and filings arrive.